Medici partner Shengnoki "first-in-class" new drug up to III

On January 06, 2021, Beijing Shengnoki Pharmaceuticals announced that its self-developed natural-source small molecule immunomodulation innovation drug Acolatin compared to the effectiveness and safety of patients with advanced hepatocellular carcinoma, randomized control, double-blind double simulation, national multi-center Phase III clinical trial, by the Independent Data Monitoring Committee (IDMC) to determine that the population of advanced patients reached the pre-set main research endpoint, the trial was successful.
as a partner of Shengnoki Pharmaceuticals, Medici congratulates Beijing Shengnoki Pharmaceuticals on its major breakthrough in the original innovation of advanced hepatocellular carcinoma.
hepatocellular carcinoma is a common malignant tumor in China.
statistics, China's annual new cases of about 466,000, and the number of deaths as high as 422,000, more than half of the world, seriously threatening people's lives and health.
Sanoki Pharmaceuticals, with its mission of "Innovative medicine for health", fits in with Medici's corporate slogan of "Innovation-Driven, Quality First" and uses modern biotechnology to develop new drugs for patients in China and around the world in the field of cancer and autoimmune diseases.
Acolatin, also known as masturbation amniotic acid, is the hydrolytic product of chinese medicine masturbation amniotic acid extract, first reported by Zhejiang University Lou Yijia in 2004 on the estrogen receptor (estrogen receptor, ER) has inhibition activity, since then, for masturbation amniotic acid in the pharmaceutical aspects of research has been carried out.
Current studies of Acolatin's anti-tumor mechanisms have shown that it regulates inflammatory and immunomodulation signaling pathways based on IL-6/JAK/STAT3 by directly binding and acting on the target proteins MyD88 and IKK alpha in the TLR/NF-kB signaling channels that play an important role in the immune system and cancer mechanism to regulate the multiple biological functions of different immune cells in tumor cells and tumor immunologic micro-environments, including promoting tumor apoptosis, inhibiting tumor cell growth, inhibiting tumor stem, inhibiting inflammatory factors IL-6, IL-8, IL-10, TNF-α expression, and suppressing Immune checkpoint PD-L1 expression.
In addition, Acolatin's multi-target mechanism enables it to improve the tumor immune micro-environment through multiple path paths, reduces resistance to PD-1 or PD-L1 antibodies, and produces synergies for tumor therapy to enhance anti-tumor efficacy.
Medesi congratulates partner Sanoki Pharmaceuticals on its landmark progress and hopes the drug will be available as soon as possible, benefiting patients and bringing healthy benefits to the general public!